Moods Disorders Completed Phase 3 Trials for Brexpiprazole (DB09128)

Also known as: Mood Disorders / Mood Disorder

IndicationStatusPhase
DBCOND0058256 (Moods Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01360866Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Treatment
NCT02196506Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious DistressTreatment
NCT01727726A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus TrialTreatment
NCT01360645Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)Treatment
NCT01360632Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)Treatment